Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2021, Issue -, Pages 1-13
Publisher
Hindawi Limited
Online
2021-05-25
DOI
10.1155/2021/9995869
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LUBAC accelerates B-cell lymphomagenesis by conferring B cells resistance to genotoxic stress
- (2020) Tomoyasu Jo et al. BLOOD
- TIMER2.0 for analysis of tumor-infiltrating immune cells
- (2020) Taiwen Li et al. NUCLEIC ACIDS RESEARCH
- TRIM35 mediates protection against influenza infection by activating TRAF3 and degrading viral PB2
- (2020) Nan Sun et al. Protein & Cell
- Circadian disruption promotes tumor-immune microenvironment remodeling favoring tumor cell proliferation
- (2020) I. Aiello et al. Science Advances
- Circadian Clocks and Cancer: Timekeeping Governs Cellular Metabolism
- (2019) Amandine Verlande et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- CRL3–SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling
- (2019) Xiaofeng Jin et al. LEUKEMIA
- Circadian clock associates with tumor microenvironment in thoracic cancers
- (2019) Yong Yang et al. Aging-US
- Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
- (2018) Frank Vari et al. BLOOD
- Gene expression markers of Tumor Infiltrating Leukocytes
- (2017) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) H. Tilly et al. ANNALS OF ONCOLOGY
- Subtype-specific therapy for DLBCL: are we there yet?
- (2015) N. Khan et al. BLOOD
- Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity
- (2014) Anne-Sophie Chretien et al. Frontiers in Immunology
- The Ubiquitin Code
- (2012) David Komander et al. Annual Review of Biochemistry
- Central and Peripheral Circadian Clocks in Mammals
- (2012) Jennifer A. Mohawk et al. Annual Review of Neuroscience
- Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma
- (2011) Deshui Jia et al. HEPATOLOGY
- What Determines the Specificity and Outcomes of Ubiquitin Signaling?
- (2010) Fumiyo Ikeda et al. CELL
- Targeting the ubiquitin system in cancer therapy
- (2009) Daniela Hoeller et al. NATURE
- Human natural killer cells
- (2008) M. A. Caligiuri BLOOD
- Targeting the ubiquitin-proteasome system for cancer therapy
- (2008) Yili Yang et al. CANCER SCIENCE
- Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis
- (2008) Na-Ri Lee et al. LEUKEMIA & LYMPHOMA
- DNA damage: ubiquitin marks the spot
- (2008) Eric J Bennett et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search